Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.
Anthony R Mato, Jeff P Sharman, Juliana Biondo, Mei Wu, Yong Mun, Su Young Kim, Kathryn Humphrey, Michelle Boyer, Qian Zhu, John F Seymour
JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
8028 Background: Ven + rituximab (VenR) has a manageable safety profile and improves survival in patients (pts) with R/R CLL, but discontinuation/interruption is frequent. We present new data from the Phase III MURANO study on the impact of Ven early discontinuation/interruption on outcomes in pts with R/R CLL. Methods: Time-dependent Cox proportional hazards regression models, stratified by 17p deletion and risk status, evaluated the impact of Ven discontinuation/interruption on investigator-assessed PFS and OS. Analyses were performed retrospectively (without type-1 error control) in intent-to-treat pts with R/R CLL from the fixed-duration VenR arm of MURANO (NCT02005471; data cut-off: Ma..View full abstract
Genentech and AbbVie provided financial support for the study.Third-party medical writing assistance under the direction of authors was provided by Rachel Dobb of Gardiner-Caldwell Communications and was funded by F. Hoffmann-La Roche Ltd